Sanofi Acquires Bioverativ For $105 Per Share In Cash, Or $11.6B
January 22, 2018 at 07:42 AM EST
Sanofi and Bioverativ have entered into a definitive agreement under which Sanofi will acquire all of the outstanding shares of Bioverativ for $105 per share in cash, representing an equity value of approximately $11.6B.
